Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
eVoss & Modus Prototype
It looks like the Modus prototype has undergone substantial ergonomic design improvements. If Alternet Systems follows up with quick updates on its contracted deliveries & charging dock installations, it would seque market legitimacy for expected announcements of marketing agreements with retailers necessary for meaningful market penetration.
Where are the new hires needed to add teeth to that shareholder letter? My 14.95 average cost shares which had been parasailing are now completely submerged.
Why doesn't the fortune 500 company acknowledge IQST's planned role in their cost saving efforts?
Is IQST so oversold on the concept of clean energy that they are willing to hide the full details of their technical skills from indifferent capital investors?
Shouldn't institutional investors have sophisticated trading analytics tools at their fingertips to enable them to set ranges for trading parameters that will more than amply maintain the solvency of their investments?
BTW, holding down share prices for 7 unsavvy Institutional Investors in order to scare off significant longterm private stakeholders is a strategically unsound path to capture sustained investments from the necessary more than 20 institutions needed for price stability & inexpensive capital formation when value accretion is prerequisite.
July 1st only equals blinded to data. It innocuously symbolizes a 1/2 calendar year.
Some of us wanted more buying coerced on Friday to enable index recalibration to add greater price stability while the wait continues.
We are speaking at cross-purposes. The limited number of this board's readers will see the differences between our objectives & chuckle over the fruitless pedantry.
Employee stock options aren't FREE. They have a contracted purchase price for common shares. CVM employee options are generally only valuable if data is good. While it is possible that some employee options will be exercised on same-day sales, it is far more likely that they will simply wait for the buyout
Why are you pushing the narrative that employees will be spending money? We are dealing with the market situation for CVM. Employees have not exercised their options prior to data release and are unlikely to risk their money on uncertain results. If data is good, the company will be bought out + cash. If data is bad, options will be worthless. There is only one condition where the price of options is relevant to employees and that condition is if the phase III data is perfectly in the middle of expectations so as to somehow keep the share price from immediately collapsing below the cost of the cheapest options & remaining moribund until an inevitable buyout coinciding with the FDA drug approval panel recommendation.
I gave no consideration to better-than nothing same-day sales , because they are less ideal than the buyout plus cash option for CVM market expectations. Do let all of us know if, during the company's long history, an employee has relied upon a brokerage loan to capture a few thousand dollars from such a sale.
Buyout Plus Cash funds the exercise of employee options. Employees are responsible for the taxable income on the exercise price & capital gains on the exercised options from the buyout price.
Normally if there is never a buyout, few, if any, employee options are exercised because of the cost.
The price of employee options are made irrelevant by the widely expected buyout plus cash event (the cash pays for the options). Beneficiaries of exercised options at higher prices will have reduced capital gains exposure than for the cheaper (older) options.
{Update] Are these 3 job postings new
1) Facilities/Maintenance Administrator | CEL-SCI https://cel-sci.com/jobs/facilities-maintenance-administrator/
2) Quality Assurance Document Control (QA/DC) Assistant I Quality Assurance Document Control (QA/DC) Assistant I
3) Validation Supervisor | CEL-SCI
https://cel-sci.com/jobs/validation-supervisor/
if so, does this mean 4 positions were filled late last week?
Has anyone else detected a 10 business day pattern between OCTQB certification & the uplist date?
StinkyBritchesBoy is working so hard this weekend that it betrays his June OPEX anxieties as if they were frenziedly agitated by an expectation that clinical data readout WILL quickly follow the swift closing of the $31 million bought deal. His prognosticating mumblings to himself from multiple devices & his fortunes invite their abrupt Clarence Beeks ending.
The AF tweet can be interpreted as indicating 15 sophisticated retail investors supplanted the hedge fund interests that had made them privy to the call & offering with their own financial objectives.
[Hiring Spree] It took nearly a month to finalize this deal Feurenstein 5.17.21 https://bit.ly/3irve2R Cel-Sci CEO Geert Kersten spoke privately with investors last week as part of a “non-deal roadshow” organized by Kingswood Capital Markets, an investment bank that has helped the drug maker raise money in the past.
I'd be really surprised if it took till the middle of june
Tweeting activity is not limited by SEC as long as the public knows which posts originate from company accounts.
Anyone suggesting the CEO cannot make social media posts immediately before the company releases data implies that he also cannot use his telephone, talk to his neighbor, etc.
Intratumoural administration & tumour tissue targeting of cancer immunotherapies https://go.nature.com/34Tr4sG
Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are revolutionizing oncology and haematology practice. With these and other immunotherapies, however, systemic biodistribution raises safety issues, potentially requiring the use of suboptimal doses or even precluding their clinical development. Delivering or attracting immune cells or immunomodulatory factors directly to the tumour and/or draining lymph nodes might overcome these problems. Hence, intratumoural delivery and tumour tissue-targeted compounds are attractive options to increase the in situ bioavailability and, thus, the efficacy of immunotherapies. In mouse models, intratumoural administration of immunostimulatory monoclonal antibodies, pattern recognition receptor agonists, genetically engineered viruses, bacteria, cytokines or immune cells can exert powerful effects not only against the injected tumours but also often against uninjected lesions (abscopal or anenestic effects). Alternatively, or additionally, biotechnology strategies are being used to achieve higher functional concentrations of immune mediators in tumour tissues, either by targeting locally overexpressed moieties or engineering ‘unmaskable’ agents to be activated by elements enriched within tumour tissues. Clinical trials evaluating these strategies are ongoing, but their development faces issues relating to the administration methodology, pharmacokinetic parameters, pharmacodynamic end points, and immunobiological and clinical response assessments. Herein, we discuss these approaches in the context of their historical development and describe the current landscape of intratumoural or tumour tissue-targeted immunotherapies.
Practical tool use has become Exceedingly TOXIC, irrational, & broken cookie jar stupid.
Living Large in Miami using shareholder wallets
The PIPE by family offices raises significant questions about insider trading & naked short selling. Threshold Security List requirements allow up to 4 consecutive days of FTD before the security is flagged. This rule matches nearly precisely volume trading of $IQST.
It is doubtful that the institutional investors & Family Offices haves sold even 1/3rd of the common shares obtained from the PIPES. They are likely teasing the float with imbalances to amplify scare tactic shakedowns by their alter ego avatars that keep manipulated & greedily expectant control of share price. They are not required to file 13Gs until after 1 calendar year has elapsed
Will we learn to what extent Multikine affects the microbiome's ability to facilitate treatment effectiveness and what the signature protein markers of responsiveness were?
innocuous
Are they incentive stock options or non-qualified or bonus? Up to 3,600,000
non-qualified stock options were approved from 2020's Def 14 A.
Why has the compensation committee approved these allotments? Who is on the compensation committee?
Are these Form 4s the 3rd of 3 parts for the study milestone & completion stock awards?
And/Or are they being doled out solely because of the technicality of having reached the anticipated study completion date resulting from the fact that the Company is under no statutory or regulatory obligation to amend the anticipated study completion date?
Fiber Optics & 5G ? Latin America
Is the IBank brutally manipulating the share price to capture a predetermined amount of OS to advance the capital formation agenda it shares with the company? Last summer it took less than 2 weeks for $ALPP to uplist to QB. the fourth week of our uplisting wait ends tuesday, Will a new excuse for delays be announced then if too many shares continue to be held by laypeople?
Small volume pre-market hours stock price manipulation is being perpetrated by commenters on this messageboard. Do not allow sympathetic charity to lead you to mistakenly attribute credibility to any commenter who relies upon first person character & life experience descriptions to underpin their messaging. Everyone here is selfish & greedy, but some conceive of their needs as being zero sum & malice dependent.
The client is the CRO who subcontracted data lock analysis and creation of the CSR.
Some commenters on here & the other messageboards routinely post fact distorting narratives to advance the financial interests of their employers. They then tactically redouble these prescribed views & pedal an illusion of credibility by using multiple devices to skirt multiple id TOS prohibitions. (Sushifishman is the worst f--ing offender)
Cheap stock options place strict upward limits on the stock price when data results are released. Who benefits most by talking down the stock & option prices of CVM? In the same light, anyone talking up the value of intermediate & long range option contracts is most likely just employed to sell junk.
Are new hires Security, Maintenance, Administrative Assistants, Legal Assistants, Pandemic Med Service Tech, & Bioassay Development???? Extrapolated! Manufacturing facility expansion must have commanded some of the new hires! It seems probable that about half of the 11 new hires during the past 12 months are Multikine related.
You are wrong. I've been checking & counting job postings on a daily basis for the last two weeks. My counts never indicated a posting had been removed, changed, or added until Friday afternoon.
For information sensitive valuations, is Friday after the close of regular trading an unusual time to post a New Job Opening (Quality Control Technical Writer) & draw attention to the fact that a prior job opening (Bioassay Development Specialist) is no longer available?
Looks like they filled a position. Will have to check the internet archive later to verify which one it was.
Next Week? vs. Cash for Gold scream sushi & the other self-interested & longtime stock prognosticators on this board Many competitors reported failed trials during HN month. While it would have been sweetly poetic to have had CVM report Multikine as a cure for HN on the last day of the month, it was always unlikely. With that being said, if the Multikine drug trial had failed, there was no shame to be found in reporting in chorus with the competitors. As such, it seems multikine may very well have proven to be an effective treatment for HN (I can't wait to learn if its effectiveness derives from its cytokine ability to disrupt cancer's energy use for cell division & metastasis thus allowing cell suicide to finally complete in host cells thereby effectively wounding the cancer with breaches penetrable by various healthy immune cells & platelets)
Joe Manchin has already stated that he will not vote for the infrastructure package if the tax rate is changed to those numbers. I'd expect the capital gains tax increase to be lowered to 25% but include a broader base of $750.000 & allow an increased home sales exclusion for single persons up to $375,000 & $750,000 for married couples. Also, I'd the bet the top income tax bracket settles at just over 38%
If CVM is sold, its CEO & board members will be highly recruited for top tier corporate governance positions that would allow them to earn a second fortune.
Exercising options on the precipice of data readout would be an ACTUAL example of illegal insider trading (and also stupid because any buyout will include Cash Plus for those options)
Multikine, the MegaBlockBuster Head & Neck Cancer drug from Cel-Sci, is so close to data readout that the CEO is now declining interviews from friendly financial media.
I look forward to seeing a state of the art cgi animated diagnostic presentation of their findings.
Tumor microenviromental response to treatment is fascinating. Looking forward to learning what Cel-Sci has discovered about tumor secretions in response to its immunotherapy treatment (i.e., what are their enzymatic/protein properties? How are they agonistically effective in responding to the body's immune responders [T Cells, Neutrophils, B Cells, Scavenger Cells, Platelets, etc]?)
Arm flailing attention seeking by the CEO is quite unusual. Legally, he can do anything but communicate that he has data, knows its results, & unofficially shares them or the release date. If he makes it onto Forbes list, what are his philanthropic intentions?
A probable Stock Plus Cash buyout converts all options & spares C-suite executives of the expense & unnecessary price trifling . When giving serious thought to this form 4 episode, I am left to conclude that it is a bit of a running joke in the respected hallways along San Tomas.